Modeling antibody drug conjugate potential using a granzyme B antibody fusion protein.

ABSTRACT:

Background

Antibody drug conjugates (ADCs) constitute a promising class of targeted anti-tumor therapeutics that harness the selectivity of monoclonal antibodies with the potency of cytotoxic drugs. ADC development is best suited to initially screening antibody candidates for desired properties that potentiate target cell cytotoxicity. However, validating and producing an optimally designed ADC requires expertise and resources not readily available to certain laboratories.

Results

In this study, we propose a novel approach to help streamline the identification of potential ADC candidates by utilizing a granzyme B (GrB)-based antibody fusion protein (AFP) for preliminary screening. GrB is a non-immunogenic serine protease expressed by immune effector cells such as CD8 + T cel

SUBMITTER: Anderson TS 

PROVIDER: S-EPMC10941411 | biostudies-literature | 2024 Mar

REPOSITORIES: biostudies-literature